Technology Holding, LLC — Department of Defense SBIR Phase I: DHA202-003

Technology Holding, LLC — SBIR Phase I award from Department of Defense.

Amount
$249,563
Agency
Department of Defense · Defense Health Program
Program / Phase
SBIR · Phase I
Topic
DHA202-003
Solicitation
20.2
NAICS
Place of performance
UT
Period
2021-02-10 → 2021-09-09

Description

Antibiotic resistant infections are a principal concern for the Department of Defense and society at large due to the current lack of available treatments. Monoclonal antibodies represent a promising drug class that could be applied to antibiotic resistant infections to harness a patients own immune system to effectively combat the invading threat. In this program we present an optimized workflow to yield high affinity monoclonal antibody candidates against surface antigens from common infectious disease which is increasingly antibiotic resistant.